


Abstract of WO2004026330

The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026330 A1

- (51) International Patent Classification⁷: A61K 38/17
- (21) International Application Number:
PCT/BE2003/000158
- (22) International Filing Date:
23 September 2003 (23.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0222014.3 23 September 2002 (23.09.2002) GB
- (71) Applicants (*for all designated States except US*): K.U. LEUVEN RESEARCH AND DEVELOPMENT [BE/BE]; Groot Begijnhof 58-59, B-3000 Leuven (BE). AARHUS UNIVERSITET [DK/DK]; Nordre Ringgade 1, DK-8000 Aarhus C (DK). AARHUS UNIVERSITY HOSPITAL [DK/DK]; Aarhus Amt, Lyseng Allé 1, DK-8270 Højbjerg (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): VAN DER BERGHE, Greta [BE/BE]; Rue de Beaumont 77, B-1390 Grez-Doiceau (BE). THIEL, Steffen [DK/DK]; Nordtøftevej 11, DK-8240 Risskov (DK). KRARUP HANSEN, Troels [DK/DK]; Bygvangen 20, DK-8200 Aarhus N (DK).
- (74) Common Representative: K.U. LEUVEN RESEARCH AND DEVELOPMENT; Dr. Ivo Roelants- IPR Officer, Groot Begijnhof 58-59, B-3000 Leuven (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:
— of inventorship (Rule 4.17(iv)) for US only
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND PREPARATIONS FOR CURING CRITICALLY ILL PATIENTS

(57) **Abstract:** The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).

WO 2004/026330 A1